Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?

Andreas S, Janson C, van den Berge M, Lahousse L.

ERJ Open Res. 2016 May 26;2(2). pii: 00055-2016. eCollection 2016 Apr.

2.

Characteristics of elderly patients with COPD and newly diagnosed lung cancer, and factors associated with treatment decision.

Qin J, Li G, Zhou J.

Int J Chron Obstruct Pulmon Dis. 2016 Jul 4;11:1515-20. doi: 10.2147/COPD.S104670. eCollection 2016.

3.

Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.

Medic G, Lindner L, van der Weijden M, Karabis A.

Adv Ther. 2016 Mar;33(3):379-99. doi: 10.1007/s12325-016-0299-4. Epub 2016 Feb 16. Review.

4.

Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.

Dahl R, Calverley PM, Anzueto A, Metzdorf N, Fowler A, Mueller A, Wise R, Dusser D.

BMJ Open. 2015 Dec 29;5(12):e009015. doi: 10.1136/bmjopen-2015-009015.

5.

The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods.

Kwak MS, Kim E, Jang EJ, Kim HJ, Lee CH.

Int J Chron Obstruct Pulmon Dis. 2015 Nov 3;10:2365-76. doi: 10.2147/COPD.S93191. eCollection 2015. Review.

6.

Prevalence of chronic obstructive pulmonary disease in asymptomatic smokers.

Sansores RH, Velázquez-Uncal M, Pérez-Bautista O, Villalba-Caloca J, Falfán-Valencia R, Ramírez-Venegas A.

Int J Chron Obstruct Pulmon Dis. 2015 Nov 2;10:2357-63. doi: 10.2147/COPD.S91742. eCollection 2015.

7.

Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.

Scott DA, Woods B, Thompson JC, Clark JF, Hawkins N, Chambers M, Celli BR, Calverley P.

BMC Pulm Med. 2015 Nov 11;15:145. doi: 10.1186/s12890-015-0138-4.

8.

Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma.

Alvarado-Gonzalez A, Arce I.

J Clin Med Res. 2015 Nov;7(11):831-9. doi: 10.14740/jocmr2305w. Epub 2015 Sep 25. Review.

9.

Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.

Huisman EL, Cockle SM, Ismaila AS, Karabis A, Punekar YS.

Int J Chron Obstruct Pulmon Dis. 2015 Sep 9;10:1863-81. doi: 10.2147/COPD.S87082. eCollection 2015. Review.

10.

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.

Anzueto A, Wise R, Calverley P, Dusser D, Tang W, Metzdorf N, Dahl R.

Respir Res. 2015 Sep 15;16:107. doi: 10.1186/s12931-015-0269-4.

11.

The inspiratory capacity/total lung capacity ratio as a predictor of survival in an emphysematous phenotype of chronic obstructive pulmonary disease.

French A, Balfe D, Mirocha JM, Falk JA, Mosenifar Z.

Int J Chron Obstruct Pulmon Dis. 2015 Jul 13;10:1305-12. doi: 10.2147/COPD.S76739. eCollection 2015.

12.

V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results.

Devillier P, Garrigue E, D'Auzers G, Monjotin N, Similowski T, Clerc T.

Respir Res. 2015 Jun 8;16:68. doi: 10.1186/s12931-015-0227-1.

13.

Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial.

Tashkin DP, Leimer I, Metzdorf N, Decramer M.

Respir Res. 2015 Jun 2;16:65. doi: 10.1186/s12931-015-0216-4.

14.

Preventing COPD exacerbations: new options for a crucial and growing problem.

Curtis JL, Martinez CH.

Fed Pract. 2014 Mar;31(3):18S-24S. No abstract available.

15.

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

Halpin DM, Dahl R, Hallmann C, Mueller A, Tashkin D.

Int J Chron Obstruct Pulmon Dis. 2015 Feb 5;10:239-59. doi: 10.2147/COPD.S75146. eCollection 2015.

16.

Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch.

Hanada S, Wada S, Ohno T, Sawaguchi H, Muraki M, Tohda Y.

Int J Chron Obstruct Pulmon Dis. 2015 Jan 6;10:69-77. doi: 10.2147/COPD.S73521. eCollection 2015.

17.

Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions.

Overington JD, Huang YC, Abramson MJ, Brown JL, Goddard JR, Bowman RV, Fong KM, Yang IA.

J Thorac Dis. 2014 Nov;6(11):1586-96. doi: 10.3978/j.issn.2072-1439.2014.11.25. Review.

18.

Prevalence and risk factors of aortic aneurysm in patients with chronic obstructive pulmonary disease.

Ando K, Kaneko N, Doi T, Aoshima M, Takahashi K.

J Thorac Dis. 2014 Oct;6(10):1388-95. doi: 10.3978/j.issn.2072-1439.2014.10.01.

19.

Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial.

Goossens LM, Leimer I, Metzdorf N, Becker K, Rutten-van Mölken MP.

BMC Pulm Med. 2014 Oct 18;14:163. doi: 10.1186/1471-2466-14-163.

20.

Epidemiology and clinical impact of major comorbidities in patients with COPD.

Smith MC, Wrobel JP.

Int J Chron Obstruct Pulmon Dis. 2014 Aug 27;9:871-88. doi: 10.2147/COPD.S49621. eCollection 2014. Review.

Supplemental Content

Support Center